ImmuCell Corp Files 8-K: Material Agreement, Officer Changes
Ticker: ICCC · Form: 8-K · Filed: Apr 7, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, officer-changes, director-changes
TL;DR
ImmuCell signed a big deal & shook up execs. Details to follow.
AI Summary
On April 4, 2025, ImmuCell Corporation entered into a material definitive agreement and reported changes in its board and officer compensation. The company also filed financial statements and exhibits related to these events. Specific details of the agreement and compensation arrangements were not provided in this initial filing.
Why It Matters
This filing indicates significant corporate actions, including a new material agreement and potential changes in executive compensation, which could impact the company's future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and changes in officers/directors, which can introduce uncertainty or signal significant strategic shifts.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- April 4, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by ImmuCell Corporation?
The filing states that ImmuCell Corporation entered into a material definitive agreement on April 4, 2025, but the specific terms and details of this agreement are not disclosed in this initial 8-K filing.
What specific changes occurred regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements, but specific names and roles are not detailed in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 4, 2025.
What is ImmuCell Corporation's principal executive office address?
ImmuCell Corporation's principal executive offices are located at 56 Evergreen Drive, Portland, Maine 04103.
What is the SIC code for ImmuCell Corporation?
ImmuCell Corporation's Standard Industrial Classification (SIC) code is 2835, which pertains to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 7, 2025 regarding IMMUCELL CORP /DE/ (ICCC).